Bergman, Andries M

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 1,511

Basis for effective combination cancer chemotherapy with antimetabolites

Peters, G. J., van der Wilt, C. L., van Moorsel, C. J. A., Kroep, J. R., Bergman, A. M., & Ackland, S. P. (2000) · Pharmacology & Therapeutics

Cancer therapeutics and mechanismsColorectal Cancer Treatments and Studies

Cited by 301

Integrative epigenetic taxonomy of primary prostate cancer

Stelloo, S., Nevedomskaya, E., Kim, Y., Schuurman, K., Valle-Encinas, E., Lobo, J., Krijgsman, O., Peeper, D. S., Chang, S. L., Feng, F. Y.-C., et al. (2018) · Nature Communications

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 154

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment

Badrising, S., van der Noort, V., van Oort, I. M., van den Berg, H. P., Los, M., Hamberg, P., Coenen, J. L., van den Eertwegh, A. J. M., de Jong, I. J., Kerver, E. D., et al. (2014) · Cancer

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 136

Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis

Stelloo, S., Nevedomskaya, E., Kim, Y., Hoekman, L., Bleijerveld, O. B., Mirza, T., Wessels, L. F. A., van Weerden, W. M., Altelaar, A. F. M., Bergman, A. M., et al. (2018) · Oncogene

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 118